Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | HTT | P42858 | 5/20 | 0.71 |
| ▸ | DDX3X | O00571 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | BAZ1A | Q9NRL2 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047211 | 0.84 | MEN1 (1.00) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL17084065 | 0.83 | MEN1 (0.96) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL4554987 | 0.82 | MEN1 (0.82) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL22092547 | 0.81 | MEN1 (0.79) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL29494985 | 0.81 | MEN1 (0.79) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL11898961 | 0.80 | DDX3X (1.00) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL6129390 | 0.80 | MEN1 (0.90) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL1463232 | 0.79 | MEN1 (0.71) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL27877544 | 0.79 | MEN1 (0.71) | MEN1KMT2AMAPTHTTDDX3X | |
| SCHEMBL27861138 | 0.79 | MEN1 (0.82) | MEN1KMT2AMAPTHTTDDX3X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | MEN1 903/4885KMT2A 1345/4885MAPT 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.